Abstract 28
It has been described that patients with chronic renal insufficiency (CRI) after RTx have a low IGF-1/IGFBP-3 MR which increases under rhGH, suggesting that this MR reflects IGF-1 bioavailability and that the increment explains the response to treatment. The aim of this study was to correlate IGF-1/IGFBP-3 MR and growth velocity (GV) after RTx. GV was calculated as SDS for bone age (BA) during the 0.5 to 1 year (y) period previous to blood sampling. Clinical material: Group (Gr)1, before rhGH, 7 prepubertal (PP) and 6 pubertal (P), total 13 patients, with post-RTx time (X±SD) 1.59±0.67 y chronological age (CA 12.9±2.6 y and BA 9.39±2.93 y; Gr2, during rhGH 2PP and 8 P (total 10) patients, with post-RTx time 2.84±1.87 y, CA 13.9±3.77 y, BA 9.20±3.30 y, and rhGH treatment duration range 1 to 3.5 y. Results: in Gr1, GV SDS was - 2.5±3.55 and IGF-1/IGFBP-3 MR 0.20±0.12; in Gr2, rhGH did not change CA-BA difference (4.67±2.58 and 4.5±2.27, before and during rhGH respectively), GV SDS was 0.87±1.98 and IGF-1/IGFBP-3 MR 0.30±0.21. GV SDS, but not IGF-1/IGFBP-3 MR, was significantly higher in Gr2 (p=0.007). No significant correlation between GV SDS and IGF-1/IGFBP-3 MR was found neither in Gr1 nor in Gr2. It is concluded that the IGF-1/IGFBP-3 MR is not an adequate parameter to evaluate IGF-1 bioavailability not response to rhGH treatment. Changes in serum IGF-2 and/or in other IGFBPs, which are not taken into account in this MR, could play a significant role in the pathophysiology of growth in CRI.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Castellano, M., Turconi, A., Rivarola, M. et al. Evaluation of the Serum IGF-1/IGFBP-3 Molar Ratio (MR) as a Parameter of Growth After Renal Transplantation (RTx), Before and During rhGH Treatment. Pediatr Res 45, 441 (1999). https://doi.org/10.1203/00006450-199903000-00051
Issue Date:
DOI: https://doi.org/10.1203/00006450-199903000-00051